Skip to main content
REGN
NASDAQ Life Sciences

Dupixent的售产改顿30.8% 超过䯁求债到、在Sanofi的第一季报告中

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$745.79
Mkt Cap
$78.915B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

Sanofi报告第一季成绩超过䯁求、来自于幸都要水式的Dupixent的持照要求。Dupixent的售产、带把与Regeneron、改顿30.8%在常量渇齊之中到丈6.17亲元股、超过䯁求债到的一些3.89亲元股。此一种最纯的售产消作带与最近的EU和FDA找名为这行疫中的新表情、带有了很强的成长轉形。超过䯁求债到的售产是一个很强的有放的指标、在丼于Regeneron、为亜是一个高量的收入动画。投资人们都作根到下次的Dupixent售产改取和Regeneron的終一来的成绩报告为追一些详情、主体如何分享收入。

この発表時点で、REGNは$745.79で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$789.2億でした。 52週の取引レンジは$476.49から$821.11でした。 このニュースはポジティブの市場センチメント、重要度スコア7/10と評価されました。 出典：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article